Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus

Journal of the American Academy of Dermatology

Volumn 58, Issue 5, 2008, Pages 796-801

  Czernik, Annette ^a   Beutner, Ernst H ^b   Bystryn, Jean Claude ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DAPSONE; DESMOGLEIN 1; DESMOGLEIN 3; IMMUNOGLOBULIN; PREDNISONE;

ADOLESCENT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MUMPS VIRUS; PEMPHIGUS; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; TREATMENT RESPONSE; VARICELLA ZOSTER VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; DESMOGLEIN 1; DESMOGLEIN 3; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; PEMPHIGUS;

EID: 41949096116     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.01.007     Document Type: Article

References (14)

1. Amagai M. Autoimmunity against desmosomal cadherins in pemphigus. J Dermatol Sci 20 (1999) 92-102
2. Bystryn J.C., and Rudolph J.L. IVIg treatment of pemphigus: how it works and how to use it. J Invest Dermatol 125 (2005) 1093-1098
3. Bystryn J.C., and Jiao D. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris. Autoimmunity 39 (2006) 601-607
4. Bystryn J.C., Schenkein I., and Uhr J.W. A model for the regulation of antibody synthesis by serum antibody. In: Amos B. (Ed). Progress in immunology Vol. 1 (1971), Academic Press, New York 627
5. Yu Z., and Lennon V.A. Mechanism of intravenous immune globulin therapy in antibody mediated autoimmune disease. N Engl J Med 340 (1999) 227-228
6. Arredondo J., Chernyavsky A.I., Karaouni A., and Grando S.A. Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in pemphigus. Am J Pathol 167 (2005) 1531-1544
7. Bystryn J.C., Jaio D., and Natow S. Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol 47 (2002) 358-363
8. Herzog S., Schmidt E., Goebeler M., Brocker E.B., and Zillikens D. Serum levels of autoantibodies to desmoglein 3 in patients with therapy-resistant pemphigus vulgaris successfully treated with adjuvant intravenous immunoglobulins. Acta Derm Venereol 84 (2004) 48-52
9. Sami N., Bhol K.C., and Ahmed A.R. Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus. Clin Immunol 105 (2002) 192-198
10. Ahmed A.R., Spigelman Z., Cavacini L.A., and Posner M.R. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 355 (2006) 1772-1779
11. Buckley R.H. IgG subclass deficiency. Clin Focus on Primary Immune Deficiencies 1 (1998) 1-4
12. Li N., Zhao M., Hilario-Vargas J., Prisayanh P., Warren S., Diaz L.A., et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 115 (2005) 3440-3450
13. Zhu X., Meng G., Dickinson B.L., Li X., Mizoguchi E., Miao L., et al. MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. J Immunol 166 (2001) 3266-3276
14. Yoshida M., Masuda A., Kuo T.T., Kobayashi K., Claypool S.M., Takagawa T., et al. IgG transport across mucosal barriers by neonatal Fc receptor for IgG and mucosal immunity. Springer Semin Immunopathol 28 (2006) 397-403